As OpenAI removed access to GPT-4o in its app on Friday, people who have come to rely on the chatbot for companionship are mourning the loss all over the world.
Clinical trials are facing new and evolving challenges as costs increase and approval timelines remain lengthy. Modernisation of processes and utilisation of novel technologies can help overcome such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results